G
GRI Bio, Inc. (GRI)
2.28
0.00 (0.00%)
Get all premium features to the best stock analysis tool
2.28
0.00 (0.00%)
GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase IIa clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis. The company’s portfolio also includes GRI-0803, a novel oral agonist of type 2 Natural Killer T cells that is in preclinical development for the treatment of autoimmune disorders; a proprietary library of 500+ compounds; and GRI-0124 and GRI-0729 for balance inflammatory immune responses. The company was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.
| Name | Position |
|---|---|
| Dr. Albert Agro Ph.D. | Co-Founder & Chief Medical Officer |
| Dr. Vipin Kumar Chaturvedi Ph.D. | Co-Founder & Chief Scientific Officer |
| Dr. W. Marc Hertz Ph.D. | Co-Founder, CEO, President & Director |
| Ms. Leanne M. Kelly | CFO & Corporate Secretary |
| Date | Type | Document |
|---|---|---|
| 2026-01-28 | 8-K | val-20260128.htm |
| 2026-01-21 | 8-K | val-20260121.htm |
| 2026-01-16 | 8-K | val-20260115.htm |
| 2026-01-15 | 8-K | val-20260115.htm |
| 2026-01-08 | 8-K | val-20260108.htm |
| 2025-12-29 | DEF 14A | gridefinitiveproxystatemen.htm |
| 2025-12-19 | PRE 14A | gripreliminaryproxystateme.htm |
| 2025-12-12 | 8-K | val-20251212.htm |
| 2025-12-10 | 8-K | val-20251210.htm |
| 2025-12-02 | 8-K | val-20251126.htm |